JD Health International Inc.
JD Health International Inc. (JDHIF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for JD Health International Inc. (JDHIF), covering cash flow, earnings, and balance sheets.
JD Health International Inc. (JDHIF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for JD Health International Inc. JDHIF financial performance.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $29.82B | $28.34B | $26.42B | $13.21B |
| Cost of Revenue | $23.21B | $21.64B | $20.76B | $10.38B |
| Gross Profit | $6.61B | $6.70B | $5.66B | $2.83B |
| Gross Profit Ratio | $0.22 | $0.24 | $0.21 | $0.21 |
| R&D Expenses | $685.42M | $645.01M | $609.63M | $304.82M |
| SG&A Expenses | $5.80B | $5.02B | $5.30B | $2.65B |
| Operating Expenses | $6.48B | $5.66B | $5.91B | $2.90B |
| Total Costs & Expenses | $29.69B | $27.31B | $26.67B | $13.28B |
| Interest Income | $0.00 | $0.00 | $1.01B | $503.74M |
| Interest Expense | $0.00 | $0.00 | $5.10M | $0.00 |
| Depreciation & Amortization | $111.48M | $103.22M | $119.53M | $28.07M |
| EBITDA | $239.37M | $1.14B | -$128.87M | -$96.13M |
| EBITDA Ratio | $0.008 | $0.04 | -$0.005 | -$0.007 |
| Operating Income | $127.89M | $1.04B | -$248.40M | -$124.20M |
| Operating Income Ratio | $0.004 | $0.04 | -$0.009 | -$0.009 |
| Other Income/Expenses (Net) | $2.23B | $1.40B | $679.46M | $555.26M |
| Income Before Tax | $2.36B | $2.44B | $900.68M | $431.06M |
| Income Before Tax Ratio | $0.08 | $0.09 | $0.03 | $0.03 |
| Income Tax Expense | $234.70M | $404.96M | $281.23M | $140.62M |
| Net Income | $2.12B | $2.04B | $580.48M | $290.24M |
| Net Income Ratio | $0.07 | $0.07 | $0.02 | $0.02 |
| EPS | $0.67 | $0.65 | $0.18 | $0.09 |
| Diluted EPS | $0.67 | $0.65 | $0.18 | $0.09 |
| Weighted Avg Shares Outstanding | $3.16B | $3.14B | $3.19B | $3.13B |
| Weighted Avg Shares Outstanding (Diluted) | $3.16B | $3.16B | $3.19B | $3.17B |
Over the last four quarters, JD Health International Inc. achieved steady financial progress, growing revenue from $13.21B in Q3 2023 to $29.82B in Q4 2024. Gross profit stayed firm with margins at 22% in Q4 2024 versus 21% in Q3 2023. Operating income totaled $127.89M in Q4 2024, maintaining a 0% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $239.37M. Net income rose to $2.12B, with EPS at $0.67. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan